NPCE: Neuropace Inc

NPCE新闻

• 10:38 Keybanc Initiates Coverage On NeuroPace with Overweight Rating, Announces Price Target of $18
• 10:38 KeyBanc开始对NeuroPace进行覆盖，给予超额评级，宣布股价目标为18美元
• 15:30 Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?
• 13:58 Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
• 17:17 NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
• 17:06 Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?
• 16:59 NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
• 21:57 NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript
• 15:22 NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up
• 21:25 NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates
• 02:35 CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates
• 05:03 NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript
• 14:23 Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
• 13:55 Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade
• 15:30 NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?
• 14:38 Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
• 15:50 NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy
• 14:58 Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?
• 14:45 NPCE Explains How NeuroPace's RNS System Makes Money
• 14:34 NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care
• 16:22 NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised
• 02:10 NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript